Next Science Ltd (AU:NXS) has released an update.
Next Science Ltd has announced the publication of a study in the Journal of Orthopaedic Surgery, demonstrating the efficacy of their surgical irrigation product, XPERIENCE™, in preventing joint infections following primary knee, hip, and shoulder replacements. The product, part of the company’s proprietary XBIO™ suite, showed a zero percent infection rate post-surgery in a study of 423 patients, signaling potential for XPERIENCE™ to become a new standard in surgical care. This peer-reviewed endorsement highlights Next Science’s commitment to reducing biofilm-based infections and supports further clinical research to establish the effectiveness of their medical technologies.
For further insights into AU:NXS stock, check out TipRanks’ Stock Analysis page.
